Cure My Disease

Don't miss your cure!

 Log in / Sign up

Texting your symptoms: a digital coach for cancer side effects?

NCT ID NCT07723495

Symptom relief Sponsor: Henry Ford Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 30, 2026 · Updated 4 times

Summary

This trial tests whether a digital platform that sends symptom check-ins and self-care tips via text message can help people with head and neck or lung cancer report their health more consistently. Participants either receive standard symptom questionnaires or get extra monitoring and guidance for managing common side effects like dry mouth or shortness of breath. The goal is to see if this approach boosts symptom reporting and helps patients feel better during treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a digital platform (CIAS) that monitors additional symptoms and provides evidence-based self-management strategies via SMS text
What this could lead to
If it works, this approach could improve how cancer patients report symptoms and manage side effects, potentially leading to better quality of life and fewer unplanned hospital visits.
What could go wrong
This is a small, early-stage trial focused on feasibility and completion rates, not on clinical outcomes. The digital tool may not work for all patients, and the self-management handbook may not be effective for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 78 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2027

An estimate. Start dates often move.

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\) Adults (≥18 years) with a diagnosis of a malignancy of head and neck or lung cancers. * 2\) Scheduled to start infusion systemic therapy in the next 4 weeks or have started infusion systemic therapy in the past 4 weeks. * 3\) Able to read and understand English. * 4\) Cognitively oriented to person, place and time (determined by recruiter). Exclusion Criteria: * 1\) Unable to read and understand English.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant head and neck neoplasm are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer head and neck cancer Head and Neck Neoplasms lung cancer lung neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignant head and neck neoplasm Malignant lung neoplasm Malignant solid neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Henry Ford Health

    Detroit, Michigan, 48202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.